Felzartamab治疗抗PLA2R抗体阳性原发性膜性肾病的1b/2a期研究
M-PLACE开放标签1b/2a期研究评估全人源抗CD38单抗felzartamab在高危抗PLA2R+原发性膜性肾病患者中的安全性与疗效,31例患者接受9次16 mg/kg输注。主要终点为治疗中出现的不良事件(TEAE)发生率与严重程度,87.1%患者发生TEAE,最常见为输注相关反应(29.0%)。免疫学应答率76.9%,部分蛋白尿缓解率34.6%,血清白蛋白升高者占76.9%。
要点
- Felzartamab耐受性可,TEAE多为轻中度,严重TEAE均缓解
- 免疫学应答(抗PLA2R滴度降≥50%)率达76.9%,起效快速
- 部分蛋白尿缓解率34.6%,血清白蛋白改善者76.9%
核心结论
- 在高危抗PLA2R+原发性膜性肾病患者中,felzartamab耐受性可,并能快速诱导部分和完全免疫学应答,部分患者蛋白尿和血清白蛋白改善。
研究设计与样本
- M-PLACE(NCT04145440)为开放标签1b/2a期研究,纳入新诊断或复发PMN患者(队列1,n=18)及免疫抑制治疗难治性PMN患者(队列2,n=13)。
- 患者接受9次felzartamab 16 mg/kg输注,24周治疗期后随访28周;主要终点为TEAE发生率和严重程度。
主要发现
- 5例(16.1%)发生严重TEAE,均缓解。
- 26例可评估疗效患者中,20例(76.9%)达到免疫学应答(抗PLA2R滴度降低≥50%),队列1为13/15(86.7%),队列2为7/11(63.6%)。
- 抗PLA2R滴度快速下降,第1周应答率44.0%,末次给药后7个月(研究结束时)应答率53.8%。
- 26例中9例(34.6%)达到部分蛋白尿缓解(UPCR降低≥50%、UPCR<3.0 g/g且eGFR稳定),队列1为7/15(46.7%),队列2为2/11(18.2%);中位随访366天。
临床怎么用
- 对于高危抗PLA2R+原发性膜性肾病患者,felzartamab可能作为快速降低抗PLA2R抗体水平的治疗选择,但需监测输注相关反应和低丙种球蛋白血症。
局限性
- 本研究为开放标签、非对照设计,样本量较小(31例),疗效评估基于部分患者,随访时间有限(中位366天)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary membranous nephropathy (PMN) is most often caused by autoantibodies to phospholipase A2 receptor (PLA2R). M-PLACE (NCT04145440) is an open-label, phase 1b/2a study that assessed the safety and efficacy of the fully human anti-CD38 monoclonal antibody felzartamab in high-risk anti-PLA2R+ PMN. METHODS: Patients with newly diagnosed or relapsed PMN (cohort 1 [C1]; n = 18) or PMN refractory to immunosuppressive therapy (IST) (cohort 2 [C2]; n = 13) received 9 infusions of felzartamab 16 mg/kg in the 24-week treatment period, followed by a 28-week follow-up. The primary end point was the incidence and severity of treatment-emergent adverse events (TEAEs). RESULTS: A total of 31 patients were enrolled and received felzartamab. Twenty-seven patients (87.1%) had TEAEs, including infusion-related reactions (IRRs) (29.0%), hypogammaglobulinemia (25.8%), peripheral edema (19.4%), and nausea (16.1%). Five patients (16.1%) had serious TEAEs that all resolved. Immunologic response (anti-PLA2R titer reduction ≥50%) was achieved by 20 of 26 efficacy-evaluable patients (76.9%) (C1, 13/15 [86.7%]; C2, 7/11 [63.6%]). Anti-PLA2R titer reductions were rapid (week 1 response, 44.0%; response 7 months after last felzartamab dose [end of study, EOS], 53.8%). Partial proteinuria remission (urine protein-to-creatinine ratio [UPCR] reduction ≥50%, UPCR <3.0 g/g, and stable estimated glomerular filtration rate [eGFR]) was achieved by 9 of 26 patients (34.6%) (C1, 7/15 [46.7%]; C2, 2/11 [18.2%]) before or at EOS (median follow-up, 366 days). Serum albumin increased from baseline to EOS in 20 of 26 patients (76.9%) (C1, 12/15 [80.0%]; C2, 8/11 [72.7%]). CONCLUSION: In this population with high-risk anti-PLA2R+ PMN, felzartamab was tolerated and resulted in rapid partial and complete immunologic responses and partial improvements in proteinuria and serum albumin in some patients.
引用
- Rovin BH, Ronco PM, Wetzels JFM, et al. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024. PMID: 39291206. doi:10.1016/j.ekir.2024.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。